SLC24A3-AS1: A Potential Drug Target and Biomarker (G100130264)

Target Name: SLC24A3-AS1

NCBI ID: G100130264

SLC24A3-AS1

Other Name(s): SLC24A3 antisense RNA 1

SLC24A3-AS1: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 2 (SLC24A3) is a gene that encodes a protein known as SLC24A3. This protein is expressed in the brain and is responsible for transmitting sodium and glucose across the blood-brain barrier. SLC24A3 has also been implicated in the pathogenesis of various neurological and psychiatric disorders, making it an attractive target for drug development.

Several studies have identified potential drug compounds that can inhibit the activity of SLC24A3. One of these compounds, a peptide named AS1, has been shown to interact strongly with SLC24A3 and inhibit its activity. This interaction between AS1 and SLC24A3 suggests that AS1 may be a suitable biomarker for tracking the efficacy of drugs that target this protein.

In addition to its potential as a drug target, SLC24A3 is also a potential biomarker for various neurological and psychiatric disorders. The SLC24A3 gene has been implicated in the development of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. In addition, SLC24A3 has been implicated in the pathogenesis of mood disorders, such as depression and anxiety.

The identification of SLC24A3 as a potential drug target and biomarker has important implications for the development of new treatments for neurological and psychiatric disorders. Targeting SLC24A3 with small molecules or other compounds that specifically interact with this protein has the potential to modulate the activity of this gene and improve the treatment outcomes for patients with these disorders.

In conclusion, SLC24A3 is a gene that has the potential to be a drug target and biomarker for various neurological and psychiatric disorders. The interaction between SLC24A3 and potential drug compounds has led to the identification of AS1, a peptide that has been shown to inhibit the activity of SLC24A3. Further studies are needed to determine the efficacy and safety of AS1 as a potential drug and to explore its potential as a biomarker for the treatment of neurological and psychiatric disorders.

Protein Name: SLC24A3 Antisense RNA 1

The "SLC24A3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC24A3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets